Additionally, Latozinemab (AL001), a monoclonal antibody targeting sortilin (SORT1) [30, 31], is under investigation not only for FTD (NCT04374136) but also for ALS (NCT05053035) and AD (NCT05363293 and NCT06079190). Here, SORT1 is linked to frontotemporal dementia.